International Medicine and Health Guidance News ›› 2023, Vol. 29 ›› Issue (24): 3532-3537.DOI: 10.3760/cma.j.issn.1007-1245.2023.24.002
• New Medical Advances • Previous Articles Next Articles
Research progress of NLRP3 inflammasome in pathogenesis of diabetic nephropathy
Li Mengjie, Liang Dong, Xing Wenhua, Lin Qianyu, Zhang Hui, Zhang Xiaomin
Department of Nephrology, Binzhou Medical University Hospital, Binzhou 256603, China
Received:
2023-05-29
Online:
2023-12-15
Published:
2024-01-04
Contact:
Zhang Xiaomin, Email: zhangxiaomin7926@126.com
Supported by:
Project of Plan of Medical and Health Science and Technology Development in Shandong Province (2017WS689); Project of Science and Technology Plan of Binzhou Medical University (BY2021KJ07)
NLRP3炎症小体在糖尿病肾病发病机制中的研究进展
李梦洁 梁栋 邢文华 林千愉 张慧 张晓敏
滨州医学院附属医院肾内科,滨州 256603
通讯作者:
张晓敏,Email:zhangxiaomin7926@126.com
基金资助:
山东省医药卫生科技发展计划项目(2017WS689);滨州医学院科技计划项目(BY2021KJ07)
Li Mengjie, Liang Dong, Xing Wenhua, Lin Qianyu, Zhang Hui, Zhang Xiaomin.
Research progress of NLRP3 inflammasome in pathogenesis of diabetic nephropathy [J]. International Medicine and Health Guidance News, 2023, 29(24): 3532-3537.
李梦洁 梁栋 邢文华 林千愉 张慧 张晓敏.
NLRP3炎症小体在糖尿病肾病发病机制中的研究进展 [J]. 国际医药卫生导报, 2023, 29(24): 3532-3537.
Add to citation manager EndNote|Ris|BibTeX
URL: http://www.imhgn.com/EN/10.3760/cma.j.issn.1007-1245.2023.24.002
[1] Weir MA, Herzog CA. Beta blockers in patients with end-stage renal disease-evidence-based recommendations[J]. Semin Dial, 2018 ,31(3):219-225. DOI: 10.1111/sdi.12691. [2] Donate-Correa J, Luis-Rodríguez D, Martín-Núñez E, et al. Inflammatory targets in diabetic nephropathy[J]. J Clin Med, 2020,9(2):458. DOI: 10.3390/jcm9020458. [3] Zhang H, Wang Z. Effect and regulation of the NLRP3 inflammasome during renal fibrosis[J]. Front Cell Dev Biol, 2020 ,7:379. DOI: 10.3389/fcell.2019.00379. [4] Yang J, Liu Z, Xiao TS. Post-translational regulation of inflammasomes[J]. Cell Mol Immunol, 2017,14(1):65-79. DOI: 10.1038/cmi.2016.29. [5] Liu P, Zhang Z, Li Y. Relevance of the pyroptosis-related inflammasome pathway in the pathogenesis of diabetic kidney disease[J]. Front Immunol, 2021 ,12:603416. DOI: 10.3389/fimmu.2021.603416. [6] Yu ZW, Zhang J, Li X, et al. A new research hot spot: the role of NLRP3 inflammasome activation, a key step in pyroptosis, in diabetes and diabetic complications[J]. Life Sci, 2020 ,240:117138. DOI: 10.1016/j.lfs.2019.117138. [7] Yang Y, Li J, Han TL, et al. Endoplasmic reticulum stress may activate NLRP3 inflammasomes via TXNIP in preeclampsia[J]. Cell Tissue Res, 2020 ,379(3):589-599. DOI: 10.1007/s00441-019-03104-9. [8] Wang S, Zhao X, Yang S, et al. Salidroside alleviates high glucose-induced oxidative stress and extracellular matrix accumulation in rat glomerular mesangial cells by the TXNIP-NLRP3 inflammasome pathway[J]. Chem Biol Interact, 2017 ,278:48-53. DOI: 10.1016/j.cbi.2017.10.012. [9] An X, Zhang Y, Cao Y, et al. Punicalagin protects diabetic nephropathy by inhibiting pyroptosis based on TXNIP/NLRP3 pathway[J]. Nutrients, 2020 ,12(5):1516. DOI: 10.3390/nu12051516. [10] Zhao W, Zhou L, Novák P, et al. Metabolic dysfunction in the regulation of the NLRP3 inflammasome activation: a potential target for diabetic nephropathy[J]. J Diabetes Res, 2022 ,2022:2193768. DOI: 10.1155/2022/2193768. [11] Li N, Zhao T, Cao Y, et al. Tangshen formula attenuates diabetic kidney injury by imparting anti-pyroptotic effects via the TXNIP-NLRP3-GSDMD axis[J]. Front Pharmacol, 2021 ,11:623489. DOI: 10.3389/fphar.2020. 623489. [12] 宋瑞婧,张欣欣,高飞,等. 加味升降散对糖尿病肾病大鼠TXNIP/NLRP3通路及足细胞焦亡的影响[J]. 中药药理与临床,2022,38(4):2-9. [13] 沈梦婷,白丹妮,王庆伟,等. 肉桂及其活性成分抗炎作用机制的研究进展[J]. 中草药,2022,53(10):3218-3225. DOI:10.7501/j.issn.0253-2670.2022.10.032. [14] Samra YA, Said HS, Elsherbiny NM, et al. Cepharanthine and piperine ameliorate diabetic nephropathy in rats: role of NF-κB and NLRP3 inflammasome[J]. Life Sci, 2016,157:187-199. DOI: 10.1016/j.lfs.2016.06.002. [15] Yaribeygi H, Simental-Mendía LE, Butler AE, et al. Protective effects of plant-derived natural products on renal complications[J]. J Cell Physiol, 2019 ,234(8):12161-12172. DOI: 10.1002/jcp.27950. [16] Shen J, Dai Z, Li Y, et al. TLR9 regulates NLRP3 inflammasome activation via the NF-kB signaling pathway in diabetic nephropathy[J]. Diabetol Metab Syndr, 2022 ,14(1):26. DOI: 10.1186/s13098-021- 00780-y. [17] Cornut M, Bourdonnay E, Henry T. Transcriptional regulation of inflammasomes[J]. Int J Mol Sci, 2020,21(21):8087. DOI: 10.3390/ijms21218087. [18] Wang Y, Yu B, Wang L, et al. Pioglitazone ameliorates glomerular NLRP3 inflammasome activation in apolipoprotein E knockout mice with diabetes mellitus[J]. PLoS One, 2017 ,12(7):e0181248. DOI: 10.1371/journal.pone.0181248. [19] 王文文,韩文贝,万毅刚,等. 糖尿病肾病NLRP3炎症小体活化的分子调控机制及中药的干预作用[J]. 中国中药杂志,2020,45(1):7-13. DOI:10.19540/j.cnki.cjcmm. 20190618.402. [20] Zhu X, Shi J, Li H. Liquiritigenin attenuates high glucose-induced mesangial matrix accumulation, oxidative stress, and inflammation by suppression of the NF-κB and NLRP3 inflammasome pathways[J]. Biomed Pharmacother, 2018 ,106:976-982. DOI: 10.1016/j.biopha.2018.07.045. [21] Tseng CY, Wang JS, Chao MW. Causation by diesel exhaust particles of endothelial dysfunctions in cytotoxicity, pro-inflammation, permeability, and apoptosis induced by ROS generation[J]. Cardiovasc Toxicol, 2017 ,17(4):384-392. DOI: 10.1007/s12012-016-9364-0. [22] Wang K, Lv Q, Miao YM, et al. Cardamonin, a natural flavone, alleviates inflammatory bowel disease by the inhibition of NLRP3 inflammasome activation via an AhR/Nrf2/NQO1 pathway[J]. Biochem Pharmacol, 2018 ,155:494-509. DOI: 10.1016/j.bcp.2018.07.039. [23] Shahzad K, Bock F, Al-Dabet MM, et al. Stabilization of endogenous Nrf2 by minocycline protects against Nlrp3-inflammasome induced diabetic nephropathy[J].Sci Rep,2016,6:34228.DOI: 10.1038/srep34228. [24] Sun X, Wang P, Yao LP, et al. Paeonol alleviated acute alcohol-induced liver injury via SIRT1/Nrf2/NF-κB signaling pathway[J]. Environ Toxicol Pharmacol,2018,60:110-117.DOI: 10.1016/j.etap.2018.04.016. [25] 张彬,张雪涟,张晨阳,等. 冠心丹参方调控Nrf2信号通路治疗糖尿病肾病的作用研究[J]. 中国中药杂志,2020,45(11):2595-2600. DOI:10.19540/j.cnki.cjcmm.20200418.401. [26] 董奥,谭小月,孔琪,等. 五味子醇提液对糖尿病肾病小鼠氧化应激的保护作用及机制研究[J]. 中草药,2019,50(24):6038-6044. DOI:10.7501/j.issn.0253-2670.2019.24.018. [27] 罗影,左中夫,程雪,等. 葛花总黄酮通过Nrf2/HO-1信号通路对1型糖尿病大鼠肾脏的保护作用[J]. 中成药,2021,43(11):3178-3182. DOI:10.3969/j.issn.1001-1528. 2021.11.047. [28] Zhu Y, Zhu C, Yang H, et al. Protective effect of ginsenoside Rg5 against kidney injury via inhibition of NLRP3 inflammasome activation and the MAPK signaling pathway in high-fat diet/streptozotocin-induced diabetic mice[J]. Pharmacol Res,2020,155:104746.DOI: 10.1016/j.phrs.2020.104746. [29] Lin J, Cheng A, Cheng K, et al. New insights into the mechanisms of pyroptosis and implications for diabetic kidney disease[J]. Int J Mol Sci, 2020,21(19):7057.DOI: 10.3390/ijms21197057. [30] He B, Li QY, Wu YY, et al. Cyclosporin a protects JEG-3 cells against oxidative stress-induced apoptosis by inhibiting the p53 and JNK/p38 signaling pathways[J]. Reprod Biol Endocrinol,2020,18(1):100.DOI: 10.1186/s12958-020-00658-0. [31] Parveen A, Jin M, Kim SY. Bioactive phytochemicals that regulate the cellular processes involved in diabetic nephropathy[J]. Phytomedicine,2018,39:146-159.DOI: 10.1016/j.phymed.2017.12.018. [32] Shi L, Hao Z, Zhang S,et al. Baicalein and baicalin alleviate acetaminophen-induced liver injury by activating Nrf2 antioxidative pathway: the involvement of ERK1/2 and PKC[J]. Biochem Pharmacol,2018,150:9-23.DOI: 10.1016/j.bcp.2018.01.026. [33] Ghonime MG, Shamaa OR, Das S, et al. Inflammasome priming by lipopolysaccharide is dependent upon ERK signaling and proteasome function[J]. J Immunol,2014,192(8):3881-3888.DOI: 10.4049/jimmunol.1301974. [34] Zahid A, Li B, Kombe AJK,et al. Pharmacological inhibitors of the NLRP3 inflammasome[J]. Front Immunol,2019 ,10:2538.DOI: 10.3389/fimmu.2019.02538. [35] Ge C , Xu M , Qin Y ,et al. Fisetin supplementation prevents high fat diet-induced diabetic nephropathy by repressing insulin resistance and RIP3-regulated inflammation[J]. Food Funct,2019,10(5):2970-2985.DOI: 10.1039/c8fo01653d. [36] 杨鹏,刘铜华,吴丽丽,等. 中药基于p38 MAPK信号通路干预糖尿病肾病的研究进展[J]. 中国实验方剂学杂志,2023,29(11):212-223. DOI:10.13422/j.cnki.syfjx.20230139. |
[1] |
Shang Guanhua, Tian Chunmei.
Research progress of Nrf2 signaling pathway as a new target for astaxanthin therapy [J]. International Medicine and Health Guidance News, 2024, 30(1): 20-24. |
[2] |
Wang Yuqin, Liu Shengxun, Peng Xinguo.
Classification and treatment progress of dyslipidemia [J]. International Medicine and Health Guidance News, 2024, 30(1): 24-27. |
[3] |
Wang Zechuan, Huang Yueqin.
Advances in targeted drug therapy for acute myeloid leukemia [J]. International Medicine and Health Guidance News, 2023, 29(8): 1045-1048. |
[4] |
Xu Shijie, Luo Zebin, Chen Xiaodong.
Application and progress of CT pulmonary angiography in diagnosis and treatment of pulmonary embolism [J]. International Medicine and Health Guidance News, 2023, 29(8): 1053-1056. |
[5] |
Zhang Heng, Pan Guangtao, Yin Ming, Zhang Ping, Yin Xia.
Progress in autologous fat transplantation in plastic surgery [J]. International Medicine and Health Guidance News, 2023, 29(7): 889-892. |
[6] |
Wu Xuemei, Zhang Yujie, Xie Shenghua.
Psoriasis and its cardiovascular system comorbidities [J]. International Medicine and Health Guidance News, 2023, 29(4): 453-456. |
[7] |
Luo Si, He Junchu, Liang Yinru, Li Zhenzhou.
High frequency ultrasound characteristics of postpartum diastasis recti abdominis and its correlation with delivery mode [J]. International Medicine and Health Guidance News, 2023, 29(24): 3529-3532. |
[8] |
Qi Yanzhi, Wu Yanping.
Research progress of iodine contrast agent examination in patients with type 2 diabetes mellitus taking metformin [J]. International Medicine and Health Guidance News, 2023, 29(24): 3537-3541. |
[9] |
Fang Xiangfang, Huang Yujie, Li Yanfeng, Wang Zhongyong.
New progress in targeted therapy for atopic dermatitis [J]. International Medicine and Health Guidance News, 2023, 29(24): 3546-3550. |
[10] |
Geng Zeyue, Zhang Xingkai, Du Gangqiang, Zhou Nan, Zhao Dongyang, Wang Zhigang.
Complications of intramedullary nailing in the treatment of infra-isthmal femoral fracture [J]. International Medicine and Health Guidance News, 2023, 29(23): 3321-3324. |
[11] |
Zhang Chenxi, Wang Pengfei, Pan Xin, Liu Ziyi, Zhang Yong.
Progress in the application of esketamine in clinical anesthesia [J]. International Medicine and Health Guidance News, 2023, 29(23): 3325-3329. |
[12] |
Xiao Xi, Shi Doufei.
Research progress on the application of vitamin C in respiratory tract infection [J]. International Medicine and Health Guidance News, 2023, 29(23): 3330-3335. |
[13] |
Si Hang, Wang Nana, Liu Susu, Zhang Qian.
Role of PP1A in cancer and research progress [J]. International Medicine and Health Guidance News, 2023, 29(23): 3336-3340. |
[14] |
Fu Zhipeng, Zheng Sheng, Yang Juan.
Advances in nutritional evaluation methods for patients with liver cirrhosis [J]. International Medicine and Health Guidance News, 2023, 29(23): 3341-3344. |
[15] |
Cai Jinfeng, Wang Hongcai, Ge Ruli.
Role of gut microbiota imbalance in alpha-synuclein induced microglia activation in patients with Parkinson's disease [J]. International Medicine and Health Guidance News, 2023, 29(22): 3153-3157. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||